Ovarian Cancer Market: Epidemiology, Therapies, Companies, DelveInsight | pharmaand GmbH, GlaxoSmithKline, Abbvie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sanky

Ovarian cancer emerging therapies, such as Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and others, are expected to boost the Ovarian cancer Market in the upcoming years.

DelveInsight has launched a new report on "Ovarian cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Ovarian cancer, historical and forecasted epidemiology as well as the Ovarian cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Ovarian cancer market report @ https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Ovarian cancer Market Report:

In 2024, the ovarian cancer market across the 7MM was valued at approximately USD 2.7 billion, with expectations for growth driven by the anticipated launch of novel therapies. Early detection remains a challenge due to the lack of a universally accepted screening method, and symptoms often go unnoticed until the disease reaches an advanced stage.
In 2024, the United States reported the highest number of new cases of high- and low-grade serous ovarian cancer among the 7MM, totaling approximately 37,600 cases. Within the EU4 and the UK, the UK led in the number of LGSOC cases, followed by Germany, while Spain reported the fewest.
For over thirty years, platinum-based chemotherapy has been the cornerstone of ovarian cancer treatment. While initially effective, many patients eventually develop resistance to platinum therapies during recurrence. In the maintenance treatment space, the market is largely led by PARP inhibitors, including ZEJULA (niraparib), LYNPARZA (olaparib), and RUBRACA (rucaparib), all approved by the US FDA. LYNPARZA leads the market, followed by ZEJULA. However, recent restrictions on PARP inhibitors reflect shifting treatment paradigms, especially regarding their long-term survival benefits, now primarily recommended for BRCA-mutated cases.
In 2024, the United States held the largest ovarian cancer market share within the 7MM, with an estimated value of approximately USD 1,922 million. Among the EU4 and the UK, Germany led the market, while Spain had the smallest share. The treatment landscape for low-grade serous ovarian cancer (LGSOC) remains significantly underserved, with TAFINLAR + MEKINIST being the only FDA-approved option. However, approval of Avutometinib + Defactinib is anticipated in 2025. In 2024, the first-line (1L) treatment market for high-grade serous ovarian cancer (HGSOC) was valued at nearly USD 1,088 million, while the LGSOC 1L market reached approximately USD 3.2 million.
In the low-grade serous ovarian cancer (LGSOC) segment, TAFINLAR + MEKINIST currently dominates. The market is expected to expand further with the anticipated 2025 approval of Avutometinib + Defactinib. Meanwhile, ELAHERE has rapidly gained traction as an antibody-drug conjugate (ADC) for FRα-positive platinum-resistant ovarian cancer, with U.S. sales surpassing USD 470 million in 2024 and global commercialization efforts accelerating.
For high-grade serous ovarian cancer (HGSOC), promising first-line combination therapies under development include JEMPERLI + niraparib + chemotherapy, and KEYTRUDA + chemotherapy followed by maintenance with LYNPARZA. Several other pipeline therapies-such as Avutometinib + Defactinib, Relacorilant, Oregovomab, Luveltamab Tazevibulin, and Raludotatug deruxtecan-could further expand treatment options and drive market growth, especially as the number of both high- and low-grade serous ovarian cancer cases rises.
In February 2025, the FDA granted Fast Track designation to CUSP06, an antibody-drug conjugate (ADC) targeting CDH6, for the treatment of patients with platinum-resistant ovarian cancer.
Key Ovarian cancer companies such as pharmaand GmbH, GlaxoSmithKline, Abbvie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others are evaluating new drugs for Ovarian cancer to improve the treatment landscape.
Promising Ovarian cancer therapies include Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and others.

Ovarian cancer Overview

Ovarian cancer treatment generally includes surgery, chemotherapy, and targeted therapies. Surgery removes cancerous tissue, while chemotherapy-delivered orally or intravenously-aims to eliminate cancer cells. Targeted therapies help stop cancer growth and are used based on specific diagnostic test results. For high-grade serous ovarian cancer (HGSOC), the most prevalent subtype, standard treatment involves surgery and chemotherapy. Early-stage patients typically undergo surgery followed by about six chemotherapy cycles, whereas advanced-stage patients may start with chemotherapy to shrink tumors, followed by surgery and additional chemo. A patient's BRCA or HRD mutation status does not change initial treatment but guides maintenance therapy, particularly with PARP inhibitors, which help prevent recurrence. Research is ongoing into new treatment approaches, including immunotherapy, vaccine therapies, and radiation techniques like intraperitoneal radiation.

However, disparities in care persist-especially among racial minorities and low-income patients-due to limited access to specialized care, geographic and financial barriers, and inadequate education about available treatments. These challenges often lead to treatment delays, reduced survival, and underuse of life-saving interventions. Early detection is also hindered by the lack of routine screening and limited awareness of BRCA testing, particularly in underserved communities. Addressing these issues will require improving access to care, enhancing education, and expanding early detection programs.

Read more about ovarian cancer, diagnosis, treatment options @ https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ovarian cancer Market Outlook

The treatment of Ovarian cancer has progressed over time, typically involving a combination of immunosuppressive therapies-such as corticosteroids, DMARDs, and biologics-alongside physical therapy and supportive care. Despite these advancements, there remains a need for more effective and targeted treatments with fewer side effects. Emerging therapies, including biologics and small-molecule inhibitors, hold promise for improving patient outcomes and shaping future market trends.

Intravenous immunoglobulin (IVIg) has shown effectiveness as a first-line monotherapy in about 50% of patients with idiopathic inflammatory myopathies, often yielding results within three weeks for responders. For cases unresponsive to standard treatments like corticosteroids, immunosuppressants, and IVIg, intravenous cyclophosphamide may be considered as a fourth-line option, though it carries significant risks and is reserved for severe, treatment-resistant cases. Treatment strategies are typically tailored to each patient, based on disease severity, treatment response, and clinical judgment.

Discover how the Ovarian cancer market is rising in the coming years @ https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ovarian cancer Emerging Drugs
Avutometinib (VS-6766) + Defactinib (VS-6063): Verastem Oncology
Raludotatug deruxtecan: Daiichi Sankyo

Ovarian cancer Emerging Drugs

RUBRACA (rucaparib): pharma& GmbH
ZEJULA (niraparib): GlaxoSmithKline

Scope of the Ovarian cancer Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Ovarian cancer Companies: pharmaand GmbH, GlaxoSmithKline, Abbvie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others
Key Ovarian cancer Therapies: Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and others
Ovarian cancer Therapeutic Assessment: Ovarian cancer current marketed and Ovarian cancer emerging therapies
Ovarian cancer Market Dynamics: Ovarian cancer market drivers and Ovarian cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Ovarian cancer Unmet Needs, KOL's views, Analyst's views, Ovarian cancer Market Access and Reimbursement

To know what's more in our Ovarian cancer report, visit https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Ovarian cancer Market Report:
Ovarian cancer market report covers a descriptive overview and comprehensive insight of the Ovarian cancer Epidemiology and Ovarian cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Ovarian cancer market report provides insights into the current and emerging therapies.
The Ovarian cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Ovarian cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ovarian cancer market.

Got queries? Click here to know more about the Ovarian cancer market Landscape https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Ovarian cancer Patient Share (%) Overview at a Glance
5. Ovarian cancer Market Overview at a Glance
6. Ovarian cancer Disease Background and Overview
7. Ovarian cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Ovarian cancer
9. Ovarian cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Ovarian cancer Emerging Therapies
12. Ovarian cancer Market Outlook
13. Country-Wise Ovarian cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Ovarian cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Ovarian cancer Market Outlook 2034 https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Ovarian cancer Pipeline Insights, DelveInsight

"Ovarian cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ovarian cancer market. A detailed picture of the Ovarian cancer pipeline landscape is provided, which includes the disease overview and Ovarian cancer treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.